Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

13 questions in 5 reviews · Movement Disorders

current versions

No studies 13 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Summary of findings for cholinesterase inhibitors vs placebo Economic outcomes · People with Parkinson's disease Interventions for preventing falls in Parkinson's disease (2022) · Cochrane	no estimate extracted	NR	No studies
Summary of findings for education vs control Rate of falls (falls per person‐year) · People with Parkinson's disease Interventions for preventing falls in Parkinson's disease (2022) · Cochrane	no estimate extracted	NR	No studies
Summary of findings for education vs control Number of people sustaining one or more fall‐related fractures · People with Parkinson's disease Interventions for preventing falls in Parkinson's disease (2022) · Cochrane	no estimate extracted	NR	No studies
Summary of findings for education vs control Quality of life · People with Parkinson's disease Interventions for preventing falls in Parkinson's disease (2022) · Cochrane	no estimate extracted	NR	No studies
Summary of findings for education vs control Adverse events · People with Parkinson's disease Interventions for preventing falls in Parkinson's disease (2022) · Cochrane	no estimate extracted	NR	No studies
Summary of findings for education vs control Economic outcomes · People with Parkinson's disease Interventions for preventing falls in Parkinson's disease (2022) · Cochrane	no estimate extracted	NR	No studies
Botulinum toxin type A vs anticholinergics Subjective evaluation of clinical status · cervical dystonia Botulinum toxin type A versus anticholinergics for cervical dystonia (2021) · Cochrane	no estimate extracted	NR	No studies
Botulinum toxin type A vs anticholinergics Duration of effect · cervical dystonia Botulinum toxin type A versus anticholinergics for cervical dystonia (2021) · Cochrane	no estimate extracted	NR	No studies
Botulinum toxin type A vs placebo Health‐related quality of life · adults with blepharospasm Botulinum toxin type A therapy for blepharospasm (2020) · Cochrane	no estimate extracted	NR	No studies
GLP‐1 receptor agonists vs placebo Serious adverse events · adults with Parkinson's disease GLP‐1 receptor agonists for Parkinson's disease (2020) · Cochrane	no estimate extracted	NR	No studies
Botulinum toxin vs Placebo Severity of phonic tics · Tourette's syndrome with motor and phonic tics Botulinum toxin for motor and phonic tics in Tourette's syndrome (2018) · Cochrane	no estimate extracted	NR	No studies
Botulinum toxin vs Placebo Sensory tics · Tourette's syndrome with motor and phonic tics Botulinum toxin for motor and phonic tics in Tourette's syndrome (2018) · Cochrane	no estimate extracted	NR	No studies
Botulinum toxin vs Placebo Development of immunoresistance against botulinum toxin · Tourette's syndrome with motor and phonic tics Botulinum toxin for motor and phonic tics in Tourette's syndrome (2018) · Cochrane	no estimate extracted	NR	No studies